Urologix seeks US OK for ThermoCath BPH (benign prostatic hyperplasia) therapy:
This article was originally published in Clinica
Urologix has filed an application with the US FDA for approval to market its minimally invasive Cooled ThermoCath system for treating benign prostatic hyperplasia (BPH). The device uses targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort, says the Minneapolis, Minnesota firm. Urologix adds that pending US approval, it anticipates launching the product in the autumn this year.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.